Evidence map›Paper›PMID 41777510›Full record

ArticleNoro psikiyatri arsivi2026

Challenging The Diagnosis of Multiple Sclerosis: Histopathological Insights Gained Through Brain Biopsies.

Esra Taşkıran, Bilgin Öztürk, Naim Ata, Şuayip Birinci, Ahmed Serkan Emekli, Murat Kürtüncü

Abstract read
In one paragraph

Article in Noro psikiyatri arsivi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Esra TaşkıranDepartment of Neurology, University of Health Science, Antalya Training and Research Hospital, Antalya, Türkiye.
Bilgin ÖztürkDepartment of Neurology, University of Health Sciences Gülhane Training and Research Hospital, Ankara,Türkiye.
Naim AtaMinistry of Health of the Republic of Türkiye, Ankara, Türkiye.
Şuayip BirinciMinistry of Health of the Republic of Türkiye, Ankara, Türkiye.
Ahmed Serkan EmekliDepartment of Neurology, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Türkiye.
Murat KürtüncüDepartment of Neurology, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: While tissue sampling through brain biopsy is rarely required throughout the Multiple sclerosis (MS) disease course, it remains essential in cases with atypical clinical or radiological findings where other diagnostic methods are inconclusive. This study aims to present brain biopsy findings in patients diagnosed with MS. Methods: MS patients were screened from the national database. Brain MRI scans of all MS patients who underwent brain biopsy were reviewed to confirm the compliance of MAGNIMS criteria. Data on MS diagnosis, biopsy date, disease-modifying therapy (DMT) use, and the duration of DMT exposure prior to biopsy were also collected. Pathology reports of brain biopsies were reviewed with these parameters. Results: Among 87,640 MS patients, 21 patients had brain biopsies after MS diagnosis, highlighting the rarity (0.02%) of this invasive procedure, with a median age at biopsy of 43 (IQR: 13) years. Pathological findings revealed 12 malignant diagnoses, including lymphoma, glioblastoma, metastasis, and nine non-malignant conditions, such as vasculitis, demyelination, and benign masses. Conclusion: Brain biopsy is rarely required in patients with MS; however, it should be considered in cases of atypical lesion development, underscoring the need for meticulous clinical monitoring.

Indexed as

Brain biopsydemyelinationdisease-modifying therapymalignancymultiple sclerosispathology

Identifiers

PMID41777510
PMCPMC12951494

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.